Olgram

Olgram develops therapeutic molecules derived from marine algae to treat immune deficiency following traumatic brain injuries and to combat chronic bacterial infections. The company utilizes a proprietary research platform to create immunotherapies focused on immunology and infectiology. Its pipeline includes the development of specific biomarkers and anti-infectives designed to prevent relapses by targeting persistent bacteria.